Shane Bohnen compensation by year
BIO-TECHNE Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2025 |
|---|---|---|
| Salary | $331,500 | $431,000 |
| Bonus | — | $0 |
| Stock awards | $499,945 | $767,575 |
| Option awards | $190,699 | $377,496 |
| Non-equity incentive | $22,100 | $386,478 |
| Pension and deferred compensation | — | $0 |
| All other | $0 | $18,183 |
| Total | $1,044,244 | $1,980,732 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 19, 2025, accession 0001308179-25-000599, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 16,770 | $862,817 | — |
| RSU | 5,006 | $257,559 | — |
| PSU | 4,802 | $247,063 | — |
| RSU | 2,259 | $116,226 | — |
| Option | 1,964 | — | $73.76 |
| Option | 1,752 | — | $94.52 |
| Option | 8,944 | — | $66.97 |
| Option | 864 | — | $120.46 |
| Option | 8,848 | — | $47.60 |
| Option | 12,226 | — | $84.61 |
| Option | 12,924 | — | $84.61 |
| Option | 13,488 | — | $74.91 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2025 proxy (filed September 19, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-17 | Grant or award derivative | — | 11,344 | $0.00 | 11,344 |
| 2026-08-17 | Grant or award derivative | — | 18,432 | $0.00 | 18,432 |
| 2026-08-15 | Exercise or conversion derivative | — | 1,669 | $0.00 | 1,669 |
| 2026-08-15 | Exercise or conversion derivative | — | 300 | $0.00 | 4,502 |
| 2026-08-15 | Disposition to the issuer derivative | — | 12,117 | $0.00 | 807 |
| 2026-08-15 | Exercise or conversion derivative | — | 49 | $0.00 | 0 |
| 2026-08-15 | Tax withholding | — | 1,343 | $72.40 | 10,360 |
| 2026-08-15 | Exercise or conversion derivative | — | 2,332 | $0.00 | 4,664 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
BIO-TECHNE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kim Kelderman | President and CEO | $8,151,181 |
| James Hippel | Executive Vice President and CFO | $7,027,382 |
| William Geist | President, Protein Sciences | $3,139,299 |
| Matthew McManus | President, Diagnostics and Spatial Biology | $2,846,619 |
| Shane Bohnen · this page | Senior Vice President and General Counsel | $1,980,732 |
The full BIO-TECHNE compensation record
free company briefThis page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-TECHNE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat